The Federal Trade Commission has voted unanimously to put pharmacy benefit managers and drugmakers "on notice" about a new enforcement policy against illegal bribes and rebate schemes that can block patient access to competing lower-cost drugs.
The federal agency said it will use its full range of legal authorities to crack down on the practice of paying rebates and fees that may exclude competitors from offering cheaper drug alternatives, according to a June 16 news release. READ MORE